In prostate cancer, despite prostate-specific antigen (PSA) screening improving detection rates, its insufficient specificity results in numerous false positives, with approximately 75% of men exhibiting elevated PSA levels harboring benign prostatic conditions upon biopsy (Wilkins et al., 2020; Catalona et al., 1999). This evidence concerns the gene KLK3 and prostate cancer.